On 12/21/23, Cytokinetics Inc (NASDAQ: CYTK) stock enjoyed a major increase of 25.5%, closing at $44.82. Moreover, exceptionally high trading volume at 468% of normal accompanied the advance. The stock has performed in line with the market over the last nine months and has risen 19.9% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.